Gemcitabine: Current role and future options in the treatment of ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 48, Issue 1, 2003, Pages 81-88

  Fruscella, Erika ^a   Gallo, Daniela ^a   Ferrandina, Gabriella ^a   D'Agostino, Giuseppe ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Ovarian cancer

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TREOSULFAN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; EDEMA; FATIGUE; FLU LIKE SYNDROME; HUMAN; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; TOXICITY;

EID: 0142154073     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00119-7     Document Type: Review

References (65)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics. Ca Cancer J. Clin. 52:2002;23-47.
2. Markman M., Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol. 10:(4):1992;513-514.
3. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8:(10):1997;963-968.
4. Ozols R.F. Management of advanced ovarian cancer consensus summary. Semin. Oncol. 27:(S2):2000;47-49.
5. Ozols R.F. Recurrent ovarian cancer: evidence based treatment. J. Clin. Oncol. 20:2002;1161-1163. (editorial).
6. Ozols R.F. Treatment of recurrent ovarian cancer: increasing options-"recurrent" results. J. Clin. Oncol. 15:1997;2177-2180. (editorial).
7. Ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15:1997;2183-2193.
8. Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum sensitive ovarian carcinoma: a Gynecology Oncology Group study. J. Clin. Oncol. 16:1998;405-410.
9. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomised phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19:2001;3312-3322.
10. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin. Oncol. 29:(S1):2002;9-10.
11. Van Moorsel C.J., Peters G.J., Pinedo H.M. Gemcitabine: future prospects of single-agent and combination studies. Oncologist. 2:(3):1997;127-134.
12. Vogelzang N.J. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin. Oncol. 29:(1 Suppl. 3):2002;40-45. (Review).
13. Mackey J.R., Mani R.S., Selner M., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58:(19):1998;4349-4357.
14. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosyl cytosine. Cancer Res. 48:(14):1988;4024-4031.
15. Huang P., Chubb S., Hertel L., Grindey G.B., Plunkett W. Action of 2′,2′-diflurodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
16. Ruiz van Haperen V.W.T., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Diflurodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem. Pharmacol. 46:1993;762-766.
17. Heinemann V., Xu Y.Z., Chubb S., et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 38:(4):1990;567-572.
18. Moog R., Burger A.M., Brandl M., et al. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother. Pharmacol. 49:2002;356-366.
19. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues: mechanism of drug resistance and reversal strategies. Leukemia. 15:(6):2001;875-890.
20. Ruiz van Haperen V.W., Veerman G., Eriksson S., Stegmann A.P., Peters G.J. Induction of resistance to 2′,2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin. Oncol. 22:(4 Suppl. 11):1995;35-41.
21. Neff T., Blau C.A. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp. Hematol. 24:(11):1996;1340-1346.
22. Peters G.J., Ruiz van Haperen V.W., Bergman A.M., et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin. Oncol. 23:(5 Suppl. 10):1996;16-24. (Review).
23. Goan Y.G., Zhou B., Hu E., Mi S., Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 59:(17):1999;4204-4207.
24. Galmarini C.M., Clarke M.L., Falette N., Puisieux A., Mackey J.R., Dumontet C. Expression of a non functional p53 affects the sensitivity of cancer cells to gemcitabine. Int. J. Cancer. 97:2002;439-445.
25. Ruiz van Haperen V.W.T., Veerman G., Eriksson S., et al. Development and molecular characterization of a 2′,2′-Diflurodeoxycytidine- resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54:1994;4138-4143.
26. Peters G.J., Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Braakhuis B.J.M. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22:(4):1995;72-79.
27. Distefano M., Ferlini C., De Vincenzo R., Gaggini C., Mancuso M., Scambia G. Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells. Oncol. Res. 12:2001;335-359.
28. Ruiz van Haperen V.W.T., Veerman G., Boven E., Noordhuis P., Vermorken J.B., Peters G.J. Schedule dependence of sensitivity to 2′,2′- diflurodeoxycytidine-(gemcitabine) in relation to accumulation and retention of its triphophate in solid tumour cell lines and solid tumours. Biochem. Pharmacol. 48:1994;1327-1339.
29. Bergman A.M., Ruiz van Haperen V.W.T., Veerman C., Kuiper C.M., Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 2:1996;521-530.
30. Boven E., Schipper H., Erkelens C.A.M., Hatty S.A., Pinedo H.M. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br. J. Cancer. 68:1993;52-56.
31. Grunewald R., Abbruzzese J., Tarassoff P., Plunkett W. Saturation of 2′,2′-diflurodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 27:1991;258-262.
32. Grunewald R., Kantarjian H., Du M., Faucher K., Tarassoff P., Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma and cellular pharmacology study. J. Clin. Oncol. 10:1992;406-413.
33. Ozols R.F. The role of gemcitabine in the treatment of ovarian cancer. Semin. Oncol. 27:2000;40-47.
34. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst. 86:1994;1530-1533.
35. Shapiro J.D., Millward M.J., Rischin D., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63:1996;89-93.
36. Friedlander M., Millward M.J., Bell D., et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol. 9:1998;1343-1345.
37. Neijt J.P., Kaufman M., Bauknecht T. Gemcitabine in pretreated ovarian cancer. Ann. Oncol. 7:1996;329P. (abstract).
38. Morhan-Ihirig C., Lembersky B., Christopherson W., Tarassoff P. A phase II evaluation of difluorodeoxycytidine (dfdc) in advanced stage refractory ovarian cancer (meeting abstract). Proc. Am. Soc. Clin. Oncol. 10:1991;A646. (abstract).
39. Markman M., Kennedy A., Webster K., et al. Phase 2 trial of single-agent gemcitabine (GEM) in platinum(PLAT)/paclitaxel(PAC) refractory ovarian cancer (ROC). Proc. Am. Soc. Clin. Oncol. 20:2001;204a. (abstr 813).
40. D'Agostino G., Amant F., Berteloot P., Scambia G., Vergote I. Phase II study of gemcitabine in recurrent platinum and paclitaxel resistant ovarian cancer. Gynecol. Oncol. 88:2003;266-269.
41. Sabbatini P., Aghajanian C., Spriggs D. Chemotherapy in gynecologic cancers. Curr. Opin. Oncol. 10:1998;429-433.
42. Colombo N., Parma G., Bocciolone L., Sideri M., Franchi D., Maggioni A. Role of chemotherapy in relapsed ovarian cancer. Crit. Rev. Oncol. Hematol. 32:1999;221-228.
43. Kunkel L.M., Evans S.S., Dottino P.R., et al. Cisplatin and gemcitabine in relapsed ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 17:1998;A1379.
44. Velasco A., Matilde X.X.X., Pérez Pérez M., et al. Gemcitabine and cisplatin as treatment for patients with platinum resistant ovarian cancer and as consolidation treatment for patients with residual disease after first-line chemotherapy. Proc. Am. Soc. Clin. Oncol. 20:2001;182b. (abstr 2477A).
45. Du Bois A., Luck H.J., Pfisterer J., et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer: a dose finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann. Oncol. 12:(8):2001;1115-1120.
46. Van Moorsel C.J., Pinedo H.M., Veerman G., et al. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem. Pharmacol. 57:1999;407-415.
47. Lentz S.E., Garcia A.A., Bookman M., et al. Phase I trial of gemcitabine and protracted etoposide in recurrent gynecological tumors: A Gynecologic Onclogy Group study. Proc. Am. Soc. Clin. Oncol. 19:2000;405a. (abstr 1604).
48. Poole C.J., Perren T., Hogberg I., et al. Phase I to investigate the optimal dose and schedule of gemcitabine and paclitaxel in combination in patients with previously treated epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;357a. (abstr 1380).
49. Roman L., Garcia A.A., Facio G., et al. Phase II study of weekly paclitaxel and gemcitabine in platinum resistant ovarian cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;220a. (abstr 877).
50. Greggi S., Salerno M.G., D'Agostino G., et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology. 60:(1):2001;19-23.
51. Zoli W., Ricotti L., Barzanti F., et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int. J. Cancer. 80:1999;413-416.
52. Chow K.U., Ries J., Weidmann E., et al. Induction of apoptosis using 2′,2′difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann. Hematol. 79:2000;485-492.
53. Gordon A., Granai C.O., Rose P.G., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 19:2000;3093-3100.
54. Hansen S.W., Tuxen M.K., Sessa C. Gemcitabine in the treatment of ovarian cancer. Ann. Oncol. 10:(S):1999;51-53.
55. D'Agostino G., Ferrandina G., Garganese G., et al. Phase I study of gemcitabine and liposomial doxorubicin in relapsed ovarian cancer. Oncology. 62:2002;110-114.
56. D'Agostino G., Ludovisi M., Ferrandina G., et al. The liposomal doxorubicin (CAE) and gemcitabine (GEM) combination is active in relapsed ovarian cancer: a phase II study. Proc. Ann. Soc. Clin. Oncol. 21:2002;875. (abstr).
57. Spanu P.G., Ferrero A.M., Fuso L., et al. Gemcitabine and vinorelbine in relapsed epithelial ovarian cancer: a phase II study. Proc. Am. Soc. Clin. Oncol. 20:2001;213a. (abstr 848).
58. Gropp M., Meier W., Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol. Oncol. 71:1998;94-98.
59. Grecu O.M., Kurbacher C.M., Mallman P., et al. Treosulfan and gemcitabine in heavily pretreated patients with breast and ovarian cancer: laboratory study and clinical pilot trial of the ISCO Clinical Study Group. Proc. Am. Soc. Clin. Oncol. 20:2001;187b. (abstr 2500).
60. Krakowski I., Petit T., Kayitalire L., et al. Gemcitabine in combination with cisplatin in advanced ovarian cancer: a phase II study. Proc. Am. Soc. Clin. Oncol. 17:1998;356a. (abstract 1373).
61. Nogué M., Cirera M., Arcusa I., et al. Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;357a. (abstr 1377).
62. Bauchnecht T., Grieshaberch C., Breitbach G.-P., et al. Gemcitabine in combination with cisplatin in previously untreated patients >60 years with Figo stage IIC or IV epithelial ovarian cancer: a phase II study: preliminary results. Proc. Am. Soc. Clin. Oncol. 17:1998;356a. (abstr 1376).
63. Hansen S.W., Anderson H., Boman K., et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc. Am. Soc. Clin. Oncol. 18:1999;357a. (abstr 1379).
64. Poole C.J., Jordan S.D., Higgins H.B., et al. A phase I intra and interpatient dose ranging trial of gemcitabine, carboplatin, and paclitaxel (GCP) in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;220a. (abstr 878).
65. Hansen S.W. Gemcitabine, platinum and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin. Oncol. 1:(Suppl. I):2002;17-19.